Ophthalmology: Questions and Answers. Current Topics in Ophthalmology. Disclosures: Common Questions:

Similar documents
The Age-Related Eye Disease Study

The Age Related Eye Disease Study

Long-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan

Update 1. Red Eye. Adenovirus Numbers 3/4/14. For Your Eyes Only 2014 Ophthalmology Update. TKorn, MD, FACS San Diego, California

Update 1. Red Eye. Adenovirus Numbers 7/29/14. Adenovirus Conjunctivitis Outbreaks. Adenovirus Conjunctivitis Management

Downloaded from:

A(REDS) to Z(inc) Nutrition for eye health


Common Causes of Vision Loss

25% of normal 2/20/2018. Practical Guidelines for the Treatment of AMD 78% 22% Overview. AMD Information Overload

Prevention and treatment of agerelated macular degeneration

Bascom Palmer Eye Institute Vitamins for Macular Degeneration

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Original Policy Date

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

Clinical Trials Related to Age Related Macular Degeneration

Vision loss in elderly. Erica Weir, April 2015

Vision loss in elderly

Age-related maculopathy and cataract surgery outcomes: visual acuity and healthrelated. life CLINICAL STUDY

Manual. Manual Welsh Eye Care Initiative. A Welsh Eye Care Initiative. Protocol. The Assessment and Management of Age-related Macular Degeneration

High Resolution Imaging in Patients with Retinal Dystrophies

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre

Widefield Retinal Imaging with Auto Fluorescence Technology in the Optometric Practice

Supplementary Online Content

Risks and Benefits of Anticoagulant and Antiplatelet Medication Use before Cataract Surgery

Downloaded from:

Background 8/11/2012. Key nutrients = Healthy balanced diet. Blindness: <6/60 in Australia. Structure of the eye. Age-related Macular Degeneration

Fundus Autofluorescence. Jonathan A. Micieli, MD Valérie Biousse, MD

Reducing vision loss in chronic eye disease

Chronic eye diseases. Title of section divider. What s new, and how GPs can help. Eg. Case Study 1. Dr Jesse Gale, ophthalmologist

Patient AB. Born in 1961 PED

Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR)

ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences

The MP-1 Microperimeter Clinical Applications in Retinal Pathologies

Retina Grand Rounds. Stephen Huddleston MD Charles Retina Institute University of Tennessee Hamilton Eye Institute

Risk Factors for Developing Cataracts

2018 MIPS Quality Category Measures and Benchmarks for Ophthalmology

Mortality following cataract surgery in patients taking warfarin

2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology

Good News for The Macular Generation. Dr Andrew Thompson FRANZCO

EYE & BRAIN HEALTH DISEASE 3x more AMD

FROM OUTDATED TO UPDATED Eminence-Based Medicine

Update in the Literature 2012

Mark T. Dunbar Disclosures. Hot Topics in Retina. The Challenge. Where is the Fluid? 4/12/2016

CATARACT IS THE LEADING

OCT Angiography The Next Frontier

FEP Medical Policy Manual

OPHTHALMOLOGY DEPARTMENT Primary care referral guidelines

Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Assisting in Ophthalmology. Copyright 2011, 2007, 2003, 1999 by Saunders, an imprint of Elsevier Inc. All rights reserved.

Relevant and Reliable Systematic Review Mapped to this Section. Relevance of Review to other sections of AAO PPP- 2011

RETINAL TOXICITY FOLLOWING CHLOROQUINE THERAPY

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014

FITEYE Tablets (Multivitamin + Minerals)

AGE-RELATED EYE DISEASE

Smoking and sight loss

Age-related Macular Degeneration (AMD) Update. Michael W. Stewart, MD Professor and Chairman Department of Ophthalmology Mayo Clinic Florida

RETINA REVEALED. Dynamic Developments in AMD Diagnosis and Treatment (2014) The Dawn of: Pharmaco-Genetics (aka Nutrigenomics) Jerome Sherman, OD

MEDICAL POLICY SUBJECT: OCULAR PHOTOSCREENING. POLICY NUMBER: CATEGORY: Technology Assessment

Which Drugs Cause Ocular Side Effects?

Often asymptomatic but can cause a reduction in BCVA and distortion of vision.

Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review

Plaquenil Maculopathy

! Honoraria. ! Kemin! Nicox! Review of Optometry! Optometric Management! VSP. ! Scientific Advisory Boards

Mark Dunbar: Disclosure

Issue 15 The following key clinical peer reviewed journals will be reviewed: MONTHLY RESEARCH UPDATE 151(3) American Journal of Ophthalmology 129(5)

8/6/17. Disclosures Aerie Pharmaceuticals Alcon BioTissue Diopsys Optovue Shire

Suggested CDR Learning Codes: 2090, 3070, 3100, 4040; Level 2 Suggested CDR Performance Indicators: 8.1.3, 8.1.4, 8.3.1,

CLINICAL SCIENCES. Utility Values and Age-related Macular Degeneration

C ataract extraction remains the most commonly performed

Speaker Disclosure Statement. " Dr. Tim Maillet and Dr. Vladimir Kozousek have no conflicts of interest to disclose.

Major new Macular Degeneration Foundation research initiative

Five Things You re Missing with Your Fundus Camera

Disclosures. Conclusion/Take Away. Further Disclosure. Start with a case.. Objectives 10/16/2018

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *

NATIONAL QUALITY FORUM

Clinical Ocular Grand Rounds

Vanderbilt Eye Institute Clinical Trials

Macular Degeneration. John Christoforidis, MD Susie Chang, MD. Assistant Professors Department of Ophthalmology Ohio State University

AGE RELATED MACULAR DEGENERATION (AMD) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016

2016 PQRS Recommended Measures for: Ophthalmology

DIABETES AND YOUR EYES. Presented by Dr. Andrea Hagler

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY

RETINA 2018 OBJECTIVES OCT VERY USEFUL INFORMATION SAFE AND FRIENDLY 1/11/2018 KELLY MITCHELL

11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES

The truth about fish oil

Perspectives on Screening for Diabetic Retinopathy. Dr. Dan Samaha, Optometrist, MSc Clinical Lecturer School of Optometry, Université de Montréal

Visit Planner (version 5.0) Return this form to front desk. Feedback provided will be incorporated into the patients registry profile.

Is cataract surgery justified in patients with age related macular degeneration? A visual function and quality of life assessment

Seong Joon Ahn *, Jooyoung Joung, Sang Hyup Lee and Byung Ro Lee *

Photocoagulation of disciform macular lesions

Katra produces IPR protected Formulations and Bioactives from Natural Sources, backed by World Class Research and adheres to International Standards

Retinopathy in a diabetic population

Glaucoma Related Morbidity at A Tertiary Care Eye Hospital

Clinical Trial Endpoints for Macular Diseases

The Foundation WHAT IS THE RETINA?

Rates and Predictors of Hydroxychloroquine Retinal Toxicity in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Nutrition & Age-Related Macular Degeneration (AMD)

Transcription:

Current Topics in Ophthalmology Ophthalmology: Questions and Answers Jacque Duncan, MD Professor, Clinical Ophthalmology UCSF Primary Care Medicine: Principles and Practice October 30, 2013 With help from: Stephen D. McLeod, Professor and Chair, UCSF Department of Ophthalmology Ayman Naseri, Professor and Vice Chair for Graduate Medical Education, UCSF Department of Ophthalmology Disclosures: I have nothing to disclose Common Questions: 1. What does my patient need before undergoing cataract surgery? 2. Are vitamins really helpful in preventing vision loss? 3. What do I need to do for patients on Plaquenil? 1

Common Questions: 1. What does my patient need before undergoing cataract surgery? 2. Are vitamins really helpful in preventing vision loss? 3. What do I need to do for patients on Plaquenil? Cataract Surgery Most commonly performed ambulatory surgery in the US Numbers will increase as population ages Should I do an extensive medical evaluation to ensure my patient is safe to undergo surgery? True False Should I do routine medical testing (EKG, CBC, renal panel) to ensure my patient is safe to undergo surgery? 1. Yes 2. No No: Cochrane Review Routine pre-operative testing does not increase the safety of cataract surgery Intraoperative events (OR 1.02, 95% CI 0.85 to 1.22) Postoperative adverse events (OR 0.96, 95% CI 0.74 to 1.24). Costs estimated to be 2.55 times higher in those with preoperative medical testing compared to those without preoperative medical testing. 91.4% one year survival rate among VA pts with high disease burden Keay L, et al. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD007392 Schein O et al. NEJM 2000; 342:168-75 Greenberg PB et al. J Cataract Refract Surg 2011; 37:970-71 2

Should I discontinue my patient s anticoagulant or antiplatelet medications before cataract surgery? 1. Yes 2. No Answer: NO Most cataract surgery is done without any injections May increase medical morbidity Ophthalmologists need to communicate with primary care providers for patients with severe systemic disease, or when more invasive ocular surgery is planned. American Academy of Ophthalmology Cataract in the Adult Eye. Preferred Practice Patterns, 2006. Chen CK, Tseng VL, Wu W-C, Greenberg PB. J Cataract Refract Surg 2010; 36:1239-40. Ong-Tone L, Paluck EC, Hart-Mitchell RD. J Cataract Refract Surg 2005;31:991-6. Common Questions: 1. What does my patient need before undergoing cataract surgery? 2. Are vitamins really helpful in preventing vision loss? 3. What do I need to do for patients on Plaquenil? Age-Related Macular Degeneration Leading Cause of Severe Central Vision Loss among people over 50 in U.S. 6 million cases in U.S. 1.75 million over age 50 have advanced AMD Prevalence increasing as population ages Population >60 will double by 2030 Number with advanced AMD will increase 50% to 2.95 M by 2020 Eye Diseases Prevalence Research Group, Arch Ophthalmol 2004;122:564-72 3

Normal Retina Normal AMD Drusen Geographic Atrophy 4

Choroidal Neovascularization 10% of patients, 90% of severe vision loss Disciform Scar Nutritional Supplements in AMD Age Related Eye Disease Study (AREDS) Double-masked, placebo-controlled, multicenter, randomized clinical trial 3,640 patients, followed at least 5 years (average 6.3 years) Randomly assigned to high doses of: 1. Antioxidants Vit C 500mg, Vit E 400 IU, -carotene 15mg 2. Zinc=80mg Zn oxide + 2mg cupric oxide 3. Antioxidants + Zinc 4. Placebo AREDS Research Group, Arch Ophthalmol 2001;119:1417-36 Percent with Advanced AMD 50 40 30 20 10 0 Risk of Developing Advanced AMD Placebo Antioxidants Zinc Antioxidants+Zinc 0 1 2 3 4 5 6 7 Years 5

Age Related Eye Disease Study (AREDS) Recommend: All people > 55 years old should have dilated eye examinations If patients have medium to high-risk AMD in either eye, or advanced AMD in 1 eye: Consider supplemental vitamin C, E, zinc +copper Add -carotene if not a smoker Quit smoking if a smoker! AREDS 2 No additional benefit to adding lutein and omega-3 fatty acid supplementation Common Questions: 1. What does my patient need before undergoing cataract surgery? 2. Are vitamins really helpful in preventing vision loss? 3. What do I need to do for patients on Plaquenil? AREDS Research Group, Arch Ophthalmol 2001;119:1417-36 AREDS Study 2 Research Group, JAMA 2013:309:2005-15 63 year old woman PMH: Lupus with Sjogren s syndrome Meds: Treated with hydroxychloroquine 400 mg daily for 25 years (lifetime dose of 3,650 grams). Weight of 135 lbs = 6.52 mg/kg/d Complained of vision loss, but her ophthalmologist records visual acuity of 20/20 OU. She was told her vision was fine and not to worry. Stopped taking hydroxychloroquine in 2005 Monitored with serial Humphrey visual field tests: Visual fields: 2003 6

Visual fields: 2007 Visual fields: 2009 Fundus Photos: 2009 Retinal Toxicity and Hydroxychloroquine Rare relative to the many thousands/millions of individuals treated Of concern because even after drug cessation there is little if any visual recovery and sometimes progression of vision loss Mechanism not clearly understood Early symptoms: paracentral vision loss with foveal sparing Moderate: bull s eye maculopathy Late: loss of peripheral visual field, night vision, widespread fundus changes Toxicity can be prevented if the drug is discontinued before advanced macular outer retinal damage has occurred Marmor MF et al, Ophthalmology 2002; 109: 1377-82 7

Retinal Toxicity and Hydroxychloroquine Risk factors: Daily dose greater than 6.5 mg/kg/d IBW Obesity: drug is not retained in fat Duration of therapy greater than 5 years After 7 years: risk increases to 1% Cumulative dose > 1000 g Renal or hepatic dysfunction Age greater than 60 years Macular or retinal disease at baseline (AMD) Ideal body weight: women = 100 lbs + 5 lbs for each inch over 5 feet men = 110 lbs + 5 lbs for each inch over 5 feet Screening Protocol Patient counseling re: risk of permanent vision loss and need for periodic exams Baseline exam, then annually after 5 years Visual field testing: Sensitivity losses 2-6 degrees from fixation White: red is sensitive but not specific Even the most subtle change should prompt objective testing and referral to an ophthalmologist! Marmor MF et al, Ophthalmology 2011; 118: 415-22 Hydroxychloroquine/Chloroquine Screening recommendations Baseline: Dilated Eye Exam and Visual Field Testing Look for pre-existing disease that could contraindicate use or complicate interpretation of screening tests Consider baseline referral to optometry or ophthalmology Routinely check for toxic daily dosing: > 6.5 mg/kg ideal body weight No additional ophthalmic testing for the first 5 years for routine patients in absence of visual symptoms, renal or hepatic disease Browning DJ, Am J Ophthalmol 2013: 155: 418-28 Marmor MF, Am J Ophthalmol 2013; 155: 413-14 Hydroxychloroquine/Chloroquine Screening recommendations Follow up: Consider annual undilated visual fields and where available, SDOCT photos: sensitive and widely available Take any visual field changes seriously and evaluate with objective tests Refer to ophthalmology with any subjective or visual field changes for more advanced objective testing Require at least 2 methods (1 objective) to confirm toxicity before recommending drug discontinuation Browning DJ, Am J Ophthalmol 2013: 155: 418-28 Marmor MF, Am J Ophthalmol 2013; 155: 413-14 8

Common Questions (and Answers): 1. What does my patient need before undergoing cataract surgery? Excellent medical care by you and communication with ophthalmology! 2. Are vitamins really helpful in preventing vision loss? YES: AREDS for AMD 3. What do I need to do for patients on Plaquenil? Baseline and regular evaluations with visual fields and eye exams by opthalmology or optometry References Keay L, Lindsley K, Tielsch J, Katz J, Schein O. Routine preoperative medical testing for cataract surgery. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD007392. DOI: 10.1002/14651858.CD007293.pub3 Schein OD, Katz J, Bass EB, Tielsch JM, Lubomski LH, Feldman MA, Petty BG, Steinberg EP. The value of routine preoperative medical testing before cataract surgery. N Engl J Med 2000;342:168-75. Greenberg PB, Tseng VL, Jiang L, Wu W-C. Cataract surgery in the very ill. J Cataract Refract Surg 2011;37:970-971 American Academy of Ophthalmology Cataract in the Adult Eye. Preferred Practice Patterns. San Francisco, CA(2006). Available at www.aao.ppp Chen CK, Tseng VL, Wu W-C, Greenberg PB. Survey of the management of antithrombotic therapy in cataract surgery patients. J Cataract Refract Surg 2010; 36:1239-40. Ong-Tone L, Paluck EC, Hart-Mitchell RD. Perioperative use of warfarin and aspirin in cataract surgery by Canadian Society of Cataract and Refractive Surgery members: Survey. J Cataract Refract Surg 2005;31:991-6. Milam AH, John SK. The Human Retina in Heath and Disease CD-ROM. Phiadelphia, PA, Scheie Eye Institute, 2001. Eye Diseases Prevalence Research Group, Arch Ophthalmol 2004;122:564-72. AREDS Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36. AREDS Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013:309:2005-15. Marmor MF et al, Ophthalmology 2002;109: 1377-82. Marmor MF et al, Ophthalmology 2011; 118: 415-22. Lyons and Severns, Am J Ophthalmol 143:801-9, 2007. Browning DJ, Am J Ophthalmol 2013: 155: 418-28 9